{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:05:25Z","timestamp":1793315125176,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Systemic sclerosis (SSc) is a rare disabling connective tissue disease with few available treatment options. Diffuse cutaneous systemic sclerosis (dcSSc) is associated with high mortality. A previous experiment has shown that JAK2 inhibitor can significantly improve skin fibrosis in bleomycin (BLM)-induced murine model, including reducing dermal thickening and collagen accumulation. We aimed to describe the efficacy of oral JAK1\/2 inhibitor baricitinib in SSc patients, especially focusing on skin fibrosis and microvascular manifestations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We described the different effects of oral selective JAK1, JAK2, or JAK3 inhibitor treatment in a BLM-induced skin fibrosis mouse model. Furthermore, 10 adult patients with dcSSc were treated with baricitinib. We assessed the changes in modified rodman skin score (mRSS) and digital ulcer net burden at week 12 and 24 from baseline. We also compared the absolute changes in scores on the Scleroderma Health Assessment Questionnaire (SHAQ) and a total score on the St. George's Respiratory Questionnaire (SGRQ) over a 24-week period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the experimental mouse model of skin fibrosis, a JAK1 and JAK2 inhibitor ameliorated skin fibrosis, and a JAK2 inhibitor had the most obvious effect. Treatment with the JAK2 inhibitor also blunted the capillary rarefaction. We demonstrated that skin fibrosis and digital ulcers were significantly relieved in 10 SSc patients treated with baricitinib. The mRSS significantly improved at week 12 from baseline, with a mean change in mRSS of \u22128.3 [95% confidence interval (CI), \u221212.03 to \u22124.574; <jats:italic>p<\/jats:italic> = 0.0007] and improved greater at week 24 to \u221211.67 (95% CI, \u221216.84 to \u22126.496; <jats:italic>p<\/jats:italic> = 0.0008). Among the four patients with digital ulcers (DU), three were completely healed at week 24, the number of ulcers in another patient was significantly reduced, and there was no patient with new ulcers. Only one adverse event (AE) of herpes zoster was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results indicate that selective JAK1 and JAK2 inhibitor alleviates skin fibrosis, and oral JAK1\/2 inhibitor baricitinib is a potentially effective treatment for dcSSc patients with skin fibrosis and DU. Baricitinib was well-tolerated by most patients in this study. Additional large clinical trials are needed to confirm our pilot findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Chinese Clinical Trial Registry Number<\/jats:title><jats:p>ChiCTR2000030995.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.859330","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T13:05:25Z","timestamp":1654520725000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":47,"title":["JAK1\/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis"],"prefix":"10.3389","volume":"9","author":[{"given":"Zhanying","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruzeng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangxia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsheng","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat Rev Dis Primers."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/art.41294","article-title":"Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis","volume":"72","author":"Spiera","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1136\/annrheumdis-2020-218447","article-title":"A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis","volume":"79","author":"Allanore","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2217\/imt-2020-0270","article-title":"The rationale for targeting the JAK\/STAT pathway in scleroderma-associated interstitial lung disease","volume":"13","author":"Talotta","year":"2021","journal-title":"Immunotherapy."},{"key":"B12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK Inhibitors: prospects in connective tissue diseases","volume":"59","author":"You","year":"2020","journal-title":"Clin Rev Allergy Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00281-015-0511-7","article-title":"Cytokines in the immunopathology of systemic sclerosis","volume":"37","author":"Raja","year":"2015","journal-title":"Semin Immunopathol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cellsig.2012.10.003","article-title":"TGF-beta signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities","volume":"25","author":"Samarakoon","year":"2013","journal-title":"Cell Signal."},{"key":"B15","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1586\/eci.11.39","article-title":"Fibroblast abnormalities in the pathogenesis of systemic sclerosis","volume":"7","author":"Usategui","year":"2011","journal-title":"Expert Rev Clin Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41467-017-01236-6","article-title":"Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis","volume":"8","author":"Chakraborty","year":"2017","journal-title":"Nat Commun."},{"key":"B17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/acr.22453","article-title":"Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial","volume":"67","author":"Strand","year":"2015","journal-title":"Arthritis Care Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.3390\/biom10071002","article-title":"JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future","volume":"10","author":"Angelini","year":"2020","journal-title":"Biomolecules"},{"key":"B19","doi-asserted-by":"publisher","first-page":"106748","DOI":"10.1016\/j.intimp.2020.106748","article-title":"Efficacy of baricitinib in treating rheumatoid arthritis: modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting","volume":"86","author":"d'Alessandro","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.5114\/reum.2020.102006","article-title":"Baricitinib for the treatment of rheumatoid arthritis","volume":"58","author":"Urits","year":"2020","journal-title":"Reumatologia."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1111\/jdv.14876","article-title":"The use of JAK inhibitors in the treatment of progressive systemic sclerosis","volume":"32","author":"Deverapalli","year":"2018","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21252","article-title":"Improvement of cutaneous inflammation and panniculitis in dermatomyositis patients by the JAK-inhibitor baricitinib","author":"Fischer","year":"2022","journal-title":"Br J Dermatol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1002\/art.34500","article-title":"JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor beta in systemic sclerosis","volume":"64","author":"Dees","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-eular.238","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/keh671","article-title":"Classification of systemic sclerosis","volume":"44","author":"Wollheim","year":"2005","journal-title":"Vis Real Rheumatol."},{"key":"B27","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1093\/rheumatology\/keaa613","article-title":"Tofacitinib as a possible treatment for skin thickening in diffuse cutaneous systemic sclerosis","volume":"60","author":"You","year":"2021","journal-title":"Rheumatology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheum."},{"key":"B30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0954-6111(06)80166-6","article-title":"The St George's respiratory questionnaire","volume":"85","author":"Jones","year":"1991","journal-title":"Respir Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e000278","DOI":"10.1136\/bmjresp-2018-000278","article-title":"Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials","volume":"5","author":"Swigris","year":"2018","journal-title":"BMJ Open Respir Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s004030000183","article-title":"Animal model of sclerotic skin. III: histopathological comparison of bleomycin-induced scleroderma in various mice strains","volume":"292","author":"Yamamoto","year":"2000","journal-title":"Arch Dermatol Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","article-title":"Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis","volume":"76","author":"Huang","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1074\/jbc.M116.773085","article-title":"Transforming growth factor-beta (TGF-beta) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway","volume":"292","author":"Tang","year":"2017","journal-title":"J Biol Chem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1136\/annrheumdis-2016-210911","article-title":"JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment","volume":"76","author":"Zhang","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.jid.2019.12.019","article-title":"Jak inhibition prevents bleomycin-induced fibrosis in mice and is effective in patients with morphea","volume":"140","author":"Damsky","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e15437","DOI":"10.1111\/dth.15437","article-title":"Janus kinase inhibitors for treatment of morphea and systemic sclerosis: a literature review","author":"McGaugh","year":"2022","journal-title":"Dermatol Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1111\/bjd.15593","article-title":"Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease","volume":"177","author":"Hurabielle","year":"2017","journal-title":"Br J Dermatol"},{"key":"B42","first-page":"2423","article-title":"Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study","volume":"34","author":"Hachulla","year":"2007","journal-title":"J Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.7326\/0003-4819-120-3-199402010-00004","article-title":"Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis A multicenter, placebo-controlled, double-blind study","volume":"120","author":"Wigley","year":"1994","journal-title":"Ann Int Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1136\/bmj.281.6247.1031","article-title":"Treatment of vasospastic disease with prostaglandin E1","volume":"281","author":"Clifford","year":"1980","journal-title":"Br Med J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2133.1987.tb04122.x","article-title":"Nifedipine in the treatment of Raynaud's phenomenon in patients with systemic sclerosis","volume":"117","author":"Meyrick Thomas","year":"1987","journal-title":"Br J Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","article-title":"Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study","volume":"75","author":"Hachulla","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med."}],"updated-by":[{"DOI":"10.3389\/fmed.2022.1125836","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:00:00Z","timestamp":1672876800000}}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.859330\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T18:49:42Z","timestamp":1672944582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.859330\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":48,"alternative-id":["10.3389\/fmed.2022.859330"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.859330","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fmed.2022.1125836","asserted-by":"object"}]},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"article-number":"859330"}}